HDV RNA assays: Performance characteristics, clinical utility, and challenges
- PMID: 37640384
- PMCID: PMC11289715
- DOI: 10.1097/HEP.0000000000000584
HDV RNA assays: Performance characteristics, clinical utility, and challenges
Erratum in
-
Erratum: HDV RNA assays: Performance characteristics, clinical utility, and challenges.Hepatology. 2025 May 1;81(5):E149. doi: 10.1097/HEP.0000000000001262. Epub 2025 Mar 21. Hepatology. 2025. PMID: 40127116 Free PMC article. No abstract available.
Abstract
Coinfection with HBV and HDV results in hepatitis D, the most severe form of chronic viral hepatitis, frequently leading to liver decompensation and HCC. Pegylated interferon alpha, the only treatment option for chronic hepatitis D for many years, has limited efficacy. New treatments are in advanced clinical development, with one recent approval. Diagnosis and antiviral treatment response monitoring are based on detection and quantification of HDV RNA. However, the development of reliable HDV RNA assays is challenged by viral heterogeneity (at least 8 different genotypes and several subgenotypes), intrahost viral diversity, rapid viral evolution, and distinct secondary structure features of HDV RNA. Different RNA extraction methodologies, primer/probe design for nucleic acid tests, lack of automation, and overall dearth of standardization across testing laboratories contribute to substantial variability in performance characteristics of research-based and commercial HDV RNA assays. A World Health Organization (WHO) standard for HDV RNA, available for about 10 years, has been used by many laboratories to determine the limit of detection of their assays and facilitates comparisons of RNA levels across study centers. Here we review challenges for robust pan genotype HDV RNA quantification, discuss particular clinical needs and the importance of reliable HDV RNA quantification in the context of drug development and patient monitoring. We summarize distinct technical features and performance characteristics of available HDV RNA assays. Finally, we provide considerations for the use of HDV RNA assays in the context of drug development and patient monitoring.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Heiner Wedemeyer consults, advises, is on the speakers’ bureau, and received grants from Gilead. He consults, advises, and is on the speakers’ bureau for Aligos Therapeutics, Altimmune, Bristol Myers Squibb, BTG, Dicerna, Enanta, Falk Foundation, Janssen, Merck KGaA, MYR GbmH, Roche, and Vir. He consults, advises, and received grants from AbbVie, Biotest AG. Thomas R. Battersby is employed by and owns stock in Gilead. He owns stock in Amgen and Roche. Jeffrey Glenn is employed by and owns stock in Eiger Biopharmaceuticals. Emmanuel Gordien consults and received grants from Eurobio and Gilead. Hema Kapoor is employed by and owns stock in Quest Diagnostics. She is employed by HK Healthcare Consultant. Oliver Lenz is employed by Janssen Pharmaceutica NV. He owns stock in Johnson & Johnson. Marc Lütgehetmann advises, is on the speakers’ bureau, and received grants from Roche. He is on the speakers’ bureau for Qiagen. Christian O. Simon is employed by and owns stock in Roche Diagnostics. Veronica Miller received grants from Abbott, Aligos Therapeutics, Altimmune, Antios Therapeutics, Assembly Biosciences, Eiger, Enyo Pharma, Gilead, GlaxoSmithKline, Hepatitis B Foundation, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology, Virion Therapeutics, and Viroclinics. Norah Terrault received grants from DSMB Moderna, Durect, Eiger, Gilead, GlaxoSmithKline, Helio Health, and Roche-Genentech. Pietro Lampertico advises and is on the speakers’ bureau for AbbVie, Aligos Therapeutics, Alnylam, Antios Therapeutics, Arrowhead, Bristol Myers Squibb, Eiger, Gilead, GlaxoSmithKline, Janssen, MSD, MYR, Roche, Spring Bank, and Vir. The remaining authors have no conflicts to report.
Figures

Similar articles
-
Accurate quantification using the new RoboGene HDV RNA Quantification Kit 3.0: A European multicenter study.J Clin Virol. 2025 Aug;179:105828. doi: 10.1016/j.jcv.2025.105828. Epub 2025 Jun 18. J Clin Virol. 2025. PMID: 40543190
-
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024.Liver Int. 2025 Jul;45(7):e70189. doi: 10.1111/liv.70189. Liver Int. 2025. PMID: 40540405 Review.
-
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.J Clin Virol. 2025 Oct;180:105850. doi: 10.1016/j.jcv.2025.105850. Epub 2025 Aug 6. J Clin Virol. 2025. PMID: 40784197
-
Prevalence, Risk Factors, and Clinical Profiles of Hepatitis D Virus in Nigeria: A Systematic Review, 2009-2024.Viruses. 2024 Oct 31;16(11):1723. doi: 10.3390/v16111723. Viruses. 2024. PMID: 39599836 Free PMC article.
-
Update on the management of HDV infection: current events and perspectives.Microb Pathog. 2025 Sep;206:107805. doi: 10.1016/j.micpath.2025.107805. Epub 2025 Jun 12. Microb Pathog. 2025. PMID: 40516886 Review.
Cited by
-
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.Liver Int. 2025 Feb;45(2):e70008. doi: 10.1111/liv.70008. Liver Int. 2025. PMID: 39853842 Free PMC article. Clinical Trial.
-
Improving Virological Monitoring of HDV Infection: A Proof-of-Concept Comparative Study of Bosphore and AltoStar® Assays in Patients Treated with Bulevirtide.Biomedicines. 2025 Jun 26;13(7):1564. doi: 10.3390/biomedicines13071564. Biomedicines. 2025. PMID: 40722639 Free PMC article.
-
Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research.Clin Transl Sci. 2024 Oct;17(10):e70051. doi: 10.1111/cts.70051. Clin Transl Sci. 2024. PMID: 39425910 Free PMC article.
-
Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.J Viral Hepat. 2025 Apr;32(4):e70022. doi: 10.1111/jvh.70022. J Viral Hepat. 2025. PMID: 40087915 Free PMC article. Clinical Trial.
-
Epidemiology of hepatitis delta virus (HDV) infection and comparison of clinical characteristics and disease progression among patients with HDV vs. hepatitis B mono-infection: real-world data from a large healthcare insurer-provider in Israel.Virol J. 2025 Aug 6;22(1):271. doi: 10.1186/s12985-025-02897-2. Virol J. 2025. PMID: 40770746 Free PMC article.
References
-
- Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. J Hepatol. 2022;77:1422–30. - PubMed
-
- Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23:117–129. - PubMed
-
- Sandmann L, Wedemeyer H. New treatments for chronic hepatitis B virus/hepatitis D virus infection. Clin Liver Dis. 2021;25:831–9. - PubMed